Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief on July 23, 2025, and is solely responsible for the information contained therein.